Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
64.79
-0.54 (-0.83%)
Aug 7, 2026, 4:00 PM EDT - Market closed
Tarsus Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 204.6 | 183.64 | 94.82 | 224.95 | 71.66 | 171.33 |
Short-Term Investments | 245.1 | 233.63 | 196.56 | 2.5 | 145.37 | 0.48 |
Cash & Short-Term Investments | 449.69 | 417.27 | 291.38 | 227.44 | 217.03 | 171.82 |
Cash Growth | 17.98% | 43.21% | 28.11% | 4.80% | 26.31% | 2.19% |
Accounts Receivable | 96.03 | 85.06 | 46.76 | 16.62 | - | - |
Other Receivables | 2.28 | 2.05 | 1.3 | 1.09 | 3.58 | 0.09 |
Total Trade Receivables | 98.31 | 87.11 | 48.06 | 17.71 | 3.58 | 0.09 |
Inventory | 4.38 | 4.37 | 2.62 | 3.11 | - | - |
Other Current Assets | 9.61 | 14.03 | 14.65 | 7.87 | 4.77 | 4.05 |
Total Current Assets | 561.99 | 522.78 | 356.71 | 256.13 | 225.38 | 175.95 |
Net Property, Plant & Equipment | 30.4 | 21.75 | 2.87 | 3.35 | 1.53 | 1.83 |
Other Intangible Assets | 6.89 | 7.37 | 8.33 | 3.87 | - | - |
Long-Term Investments | 6.68 | 3.87 | 3 | 0.63 | 0.37 | - |
Other Long-Term Assets | 5.19 | 6.4 | 6.09 | 1.51 | 0.59 | 1.13 |
Total Assets | 611.14 | 562.16 | 376.99 | 265.49 | 227.86 | 178.91 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 40.14 | 16.39 | 9.42 | 23.69 | 9.91 | 8.68 |
Accrued Expenses | 123.73 | 101.53 | 55.37 | 13.25 | 5.52 | 2.8 |
Total Current Liabilities | 175.75 | 135.7 | 80.61 | 36.94 | 15.43 | 11.48 |
Long-Term Debt | 72.76 | 72.44 | 71.85 | 29.82 | 19.43 | - |
Other Long-Term Liabilities | 15.9 | 10.6 | - | 1.75 | 0.1 | 0.7 |
Total Long-Term Liabilities | 88.66 | 83.04 | 71.85 | 31.57 | 19.53 | 0.7 |
Total Liabilities | 264.41 | 218.73 | 152.46 | 68.5 | 34.96 | 12.18 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
Additional Paid-in Capital | 799.43 | 769.67 | 584.56 | 441.64 | 301.73 | 213.4 |
Accumulated Other Comprehensive Income | -0.56 | 0.38 | 0.18 | -0 | -0.07 | - |
Retained Earnings | -452.15 | -426.63 | -360.21 | -244.66 | -108.76 | -46.67 |
Shareholders' Equity | 346.73 | 343.43 | 224.53 | 196.99 | 192.9 | 166.73 |
Total Liabilities & Equity | 611.14 | 562.16 | 376.99 | 265.49 | 227.86 | 178.91 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 72.76 | 72.44 | 71.85 | 29.82 | 19.43 | 0 |
Net Cash (Debt) | 376.93 | 344.83 | 219.53 | 197.62 | 197.59 | 171.82 |
Net Cash Growth | 21.98% | 57.08% | 11.09% | 0.02% | 15.00% | 2.19% |
Net Cash Per Share | 8.78 | 8.25 | 5.84 | 6.73 | 8.03 | 8.36 |
Book Value | 346.73 | 343.43 | 224.53 | 196.99 | 192.9 | 166.73 |
Book Value Per Share | 8.08 | 8.22 | 5.97 | 6.70 | 7.84 | 8.11 |
Tangible Book Value | 339.85 | 336.06 | 216.21 | 193.12 | 192.9 | 166.73 |
Tangible Book Value Per Share | 7.92 | 8.04 | 5.75 | 6.57 | 7.84 | 8.11 |